5:28 PM
 | 
Sep 09, 2013
 |  BC Extra  |  Top Story

Biogen Idec, Isis in fourth antisense deal

Isis Pharmaceuticals Inc. (NASDAQ:ISIS) was up $3.89 (14%) to $31.81 on Monday after announcing it will receive $100 million up front from Biogen Idec Inc. (NASDAQ:BIIB) for an antisense discovery and development deal focused on neurological diseases. During a six-year research phase, the partners will use Isis' antisense technology to...

Read the full 240 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >